<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685345</url>
  </required_header>
  <id_info>
    <org_study_id>DS8500-A-J204</org_study_id>
    <nct_id>NCT02685345</nct_id>
  </id_info>
  <brief_title>A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, add-on Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus Receiving Sitagliptin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mediscience Planning, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with
      placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with type 2 diabetes mellitus being treated with sitagliptin, efficacy and safety
      of DS-8500a are to be evaluated after 28-day multiple oral administration of DS-8500a at 25
      or 75 mg, in a double-blind, placebo-controlled, parallel-group comparison study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 24 hour weighted mean glucose</measure>
    <time_frame>baseline (Day -1) to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in fasting plasma glucose</measure>
    <time_frame>baseline (Day -1) to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma glucose</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Day −1 and Day 28: Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast; 0.5, 1, 2, and 4 hours after starting lunch before evening meal; 0.5, 1, 2, and 4 hours after starting evening meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glycoalbumin</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum insulin</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Day −1 and Day 28: Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast; 0.5, 1, 2, and 4 hours after starting lunch before evening meal; 0.5, 1, 2, and 4 hours after starting evening meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in proinsulin</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-peptide</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in PYY (pancreatic peptide YY3-36)</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GLP-1 (Glucagon-like peptide-1)</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in active GLP-1 (Glucagon-like peptide-1)</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GIP (Gastric inhibitory polypeptide)</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total glucagon</measure>
    <time_frame>baseline (Day -1) and Day 28</time_frame>
    <description>Before breakfast; 0.5, 1, 2, and 4 hours after starting breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total total cholesterol</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total HDL (high density lipoprotein) cholesterol</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total LDL (low density lipoprotein) cholesterol</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total triglyceride</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and severity of adverse events</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived plasma glucose AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from plasma glucose; AUC0-24h, AUC 0-4h, AUC4-8h, AUC9-13h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived serum insulin AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from serum insulin; AUC0-24h, AUC 0-4h, AUC4-8h, AUC9-13h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived C-peptide AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from C-peptide; AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived PYY AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from PYY; AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived total GLP-1 AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from total GLP-1; AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived active GLP-1 AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from active GLP-1; AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived total GIP AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from total GIP; AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in derived glucagon AUC</measure>
    <time_frame>baseline (Day -1) to after dosing on Day 28</time_frame>
    <description>change in pharmacodynamic parameters derived from glucagon; AUC0-4h</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DS-8500a 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-8500a 75 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablets, orally, once daily for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8500a 25 mg</intervention_name>
    <arm_group_label>DS-8500a 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8500a 75 mg</intervention_name>
    <arm_group_label>DS-8500a 75 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients with type 2 diabetes

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Patients who have been treated with sitagliptin 50 mg monotherapy for the treatment of
             type 2 diabetes mellitus

          -  Patients who have HbA1c ≥ 7.0% and &lt; 9.0%

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or
             ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with clinically evident renal impairment (estimated glomerular filtration
             rate [eGFR] of &lt; 45 mL/min per 1.73 m2) or clinically significant renal disease

          -  Patients with fasting plasma glucose ≥ 240 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuo Terauchi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yokohama City University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Yodogawaku</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>adult</keyword>
  <keyword>Phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

